GE Healthcare News
-
Precision NanoSystems And Aurora Vaccines Join Forces To Accelerate The Development Of Vaccine Candidate For Hepatitis C Virus
6/23/2023
Global leader in non-viral delivery of genomic medicines, Precision NanoSystems (PNI), entered into a strategic collaboration agreement with Aurora Vaccines to accelerate the development and manufacture of its Hepatitis C vaccine candidate. PNI will share its expertise in the development of the RNA payload platform and its proprietary lipid nanoparticle (LNP) platforms to help bring Aurora’s RNA-LNP vaccine candidate for the prevention of Hepatitis C virus (HCV) infection to a Phase I clinical trial.
-
Precision NanoSystems And Replicate Bioscience In Licensing Deal To Scale Up Genomic Medicines
7/26/2022
In a move that signifies the heightened focus on mRNA as a key tool in human health, Precision NanoSystems (PNI) and Replicate Bioscience will enter a licensing agreement to accelerate the creation, scale-up, and delivery of self-replicating RNA (srRNA) therapies.